1. Nystrom AM, Wooley KL. The importance of chemistry in creating well-defined nanoscopic embedded therapeutics: devices capable of the dual functions of imaging and therapy. Acc. Chem. Res. 2011; 44:969–978. [PubMed: 21675721]
2. Von Maltzahn G, Park JH, Lin KY, Singh N, Schwoppe C, Mesters R, Berdel WE, Ruoslahti E, Sailor MJ, Bhatia SN. Nanoparticles that communicate in vivo to amplify tumour targeting. Nat. Mater. 2011; 10:545–552. [PubMed: 21685903]
3.Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature.2010; 464:1067–1070. [PubMed: 20305636]
4. Zhang K, Fang H, Shen G, Taylor JS, Wooley KL. Well-defined cationic shell crosslinked nanoparticles for efficient delivery of DNA or peptide nucleic acids. Proc. Am. Thorac. Soc. 2009; 6:450–457. [PubMed: 19687218]
5. Elsabahy, M.; Dufresne, MH.;Leroux, JC. In Materials for Nanomedicine.Torchilin, V.; Amiji, M., editors. Hackensack: Pan Stanford Publishing; 2010. p. 169-234.
6.B.Panchapakesan, B. Book-Newell, P. Sethu, M. Rao, and J. Irudayaraj,“Goldnanoprobesfortheranostics,”Nanomedicine, vol.6,pp.1787–1811,2011.
7. D.Pissuwan, T. Niidome, and M. B. Cortie,“The forthcoming applications of gold nanoparticles in drug and gene delivery systems,”JournalofControlledRelease,vol.149,no.1,pp.65–71, 2011.
8. A. S. Thakor, J. Jokerst, C. Zavaleta, T. F. Massoud, and S. S. Gambhir, “Gold nanoparticles: a revival in precious metal administrationtopatients,”NanoLetters,vol.11,pp.4029–4036, 2011.
9. R. T. Tom, V. Surayanarayanan, P.G. Reddy, S.Baskaran andT.Pradeep,“Ciprofloxacin-protectedgoldnanoparticles,”Langmuir,vol.20,no.5,pp.1909–1914,2004
10. G. E. Craig, S. D. Brown, D. A. Lamprou, D. Graham, and N. J. Wheate, “Cisplatin-tethered gold nanoparticles that exhibit enhanced reproducibility, drug loading, and stability: a step closer to pharmaceutical approval?” Inorganic Chemistry, vol. 51,pp.3490–3497,2012.
11. C. A. Simpson, J. Salleng K, D. E. Cliffel, and D. L. Feldheim, “Invivotoxicity,biodistribution,andclearanceofglutathionecoated gold nanoparticles,” Nanomedicine, vol. 9, pp. 257–263, 2013.
12.K. Song, P. Xu, Y. Meng et al., “Smart gold nanoparticles enhance killing effect on cancer cells,” International Journal of Oncology,vol.42,no.2,pp.597–608,2012.
13. S. Guerrero, J. R. Herance, S. Rojas et al., “Synthesis and in vivoevaluationofthebiodistributionofa18F-labeledconjugate gold-nanoparticle-peptide with potential biomedical application,”BioconjugateChemistry,vol.23,pp.399–408,2012.
14.Giljohann DA, Seferos DS, Daniel WL, Massich MD, Patel PC, Mirkin CA. Gold nanoparticles for biology and medicine. AngewChemInt Ed Engl. 2010;49(19):3280–3294.
15.Ghosh P, Han G, De M, Kim CK, Rotello VM. Gold nanoparticles in delivery applications. Ad Drug Deliv Rev. 2008;60(11):1307–1315.
16. Salam HA, Rajiv P, Kamaraj M, Jagadeeswaran P, Gunalan S, Sivaraj R. Plants: green route for nanoparticle synthesis. Int Res J Biol Sci. 2012; 1(5):85–90.
17. Shukla D, Vankar PS. Synthesis of plant parts mediated gold nanoparticles. Int J Green Nanotechnol. 2012;4(3):277–288.
18.Mittal AK, Chisti Y, Banerjee UC. Synthesis of metallic nanoparticles using plant extracts. Biotechnol Adv. 2013;31(2):346–356.
19.Das SK, Marsili E. A green chemical approach for the synthesis of gold nanoparticles: characterization and mechanistic aspect. Rev Environ SciBiotechnol. 2010;9(3):199–204.
20.ChathaSAS ,Hussain AI, Asad R, et al.(2014) Bioactive components and antioxidant properties of Terminaliaarjuna L. extracts. J Food Process Technol 5:1–5.
21. Nelson SD. Mechanisms of the formation and disposition of reactive metabolites that can cause acute liver injury. Drug Metab Rev 1995; 27:147- 77.
22. Trumper L, Monasterolo LA, and Elias MM. Probenecid protects against in vitro acetaminophen induced nephrotoxicity in male Wistar rats. J PharmacolExpTherapeat1998; 283: 606-10.
23.Jaeschke H, Williams CD, Ramachandran A, et al. Acetaminophen hepatotoxicity and repair: the role of sterile inflammation and innate immunity. Liver Int 2012;32:8-20.
24.Zolnik BS, Gonzalez-Fernandez A, Sadrieh N, Dobrovolskaia MA. Nanoparticles and the immune system.Endocrinology.2010; 151:458–465.
25.Mitra M, Bandyopadhyay A, Gouriprasad D, Nandi DK.Protective Role of Green Synthesized Gold Nanoparticles usingTerminaliaarjunaagainstAcetaminophen Induced Hematological Alterations in Male Wistar Rats.J Nanomed Nanotechnol.2019;10, doi:10.4172/2157-7439. 1000530.
26. Tirmenstein MA, Nelson SP. Sub cellular binding and effects on calcium homeostasis produced by acetaminophen and a non-hepatotoxic regioisomer3-hydroxyacetanilide in mouse liver. J BiolChem 1989; 264: 9814-9819.
27.Vermeulen NPE, Bessems JGM, Van DE, Straat R. Molecular aspects of paracetamol-induced hepatotoxicity and its mechanism based prevention. Drug Metab Rev 1992; 24: 367-407.
28. Hanawa N, Shinohara M, Saberi B, et al. Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury. J BiolChem 2008;283:13565-77.
29.Chambers JW, LoGrasso PV. Mitochondrial c-Jun N-terminal kinase (JNK) signaling initiates physiological changes resulting in amplification of reactive oxygen species generation. J BiolChem 2011;286:16052-62.
30. Dahlin DC, Miwa GT, Lu AY, et al. N-acetyl-pbenzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. ProcNatlAcadSci U S A 1984;81:1327-31.
31. Martin-Murphy BV, Holt MP, Ju C. The role of damage associated molecular pattern molecules in acetaminophen-induced liver injury in mice. ToxicolLett 2010;192:387-94.
32. Han D, Shinohara M, Ybanez MD, et al. Signal transduction pathways involved in drug-induced liver injury. HandbExpPharmacol 2010:267-310.
33.Larsen FS, Wendon J. Understanding paracetamolinduced liver failure. Intensive Care Med 2014;40:888-90.
34.Horii, Y., Iwano, M., Hirata, E., Shiiki, M., Fujii, Y., Dohi, K. and Ishikawa, H. (1993) Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis. Kidney Int. 39(Suppl), S71-75.
35. Baron, S., Tyring, S. K., Fleischmann, W. R. Jr., Coppenhaver, D. H., Niesel, D. W., Klimpel, G. R., Stanton, G. J. and Hughes, T. K. (1991) The interferons. Mechanisms of action and clinical applications. JAMA 266, 1375-1383.
36.Finn, W. and Porter, G. (2003) Urinary biomarkers and nephrotoxicity. Clinical Nephrotoxins (2nd ed), pp. 621-655. Kluwer Academic Publishers, Massachusetts.
37. Ichimura, T., Bonventre, J. V., Bailly, V., Wei, H., Hession, C. A., Cate, R. L. and Sanicola, M. (1998) Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J. Biol. Chem. 273, 4135-4142.
38.Shaw PJ, Hopfensperger MJ, Ganey PE, Roth RA. Lipopolysaccharide and trovafloxacincoexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factoralpha. Toxicological Sciences. 2007 Aug 19;100(1):259-66.
39.Dinarello CA. Proinflammatory cytokines.Chest. 2000 Aug 1;118(2):503-8.